These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 7484420)

  • 1. Biochemistry and cell biology of angiotensin-converting enzyme and converting enzyme inhibitors.
    Berecek KH; Zhang L
    Adv Exp Med Biol; 1995; 377():141-68. PubMed ID: 7484420
    [No Abstract]   [Full Text] [Related]  

  • 2. [Intervention in the renin-angiotensin and kallikrein-kinin systems. Pharmacologic basis of the action of ACE inhibitors].
    Linz W; Busch AE
    Pharm Unserer Zeit; 2003; 32(1):18-22. PubMed ID: 12577756
    [No Abstract]   [Full Text] [Related]  

  • 3. Manipulating the renin-angiotensin system: more than we bargained for?
    Gardner DG
    Am J Med; 2002 Feb; 112(2):152-3. PubMed ID: 11835956
    [No Abstract]   [Full Text] [Related]  

  • 4. [What have we learned from converting enzyme inhibitors on renin-angiotensin system?].
    Waeber B; Nussberger J; Brunner HR
    Rev Prat; 1992 Dec; 42(20):2529-32. PubMed ID: 1338608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Report on the fifth annual Laragh conference: Interaction of the angiotensin converting enzyme (ACE) with the renin-angiotensin system, the kinin system and beyond.
    Gavras H
    Am J Hypertens; 2005 Jan; 18(1):1-2. PubMed ID: 15691609
    [No Abstract]   [Full Text] [Related]  

  • 6. Orally administered angiotensin-converting enzyme-inhibitors captopril and isoleucine-proline-proline have distinct effects on local renin-angiotensin system and corticosterone synthesis in dextran sulfate sodium-induced colitis in mice.
    Salmenkari H; Holappa M; Forsgard RA; Korpela R; Vapaatalo H
    J Physiol Pharmacol; 2017 Jun; 68(3):355-362. PubMed ID: 28820392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design.
    Douglas RG; Ehlers MR; Sturrock ED
    Clin Exp Pharmacol Physiol; 2013 Aug; 40(8):535-41. PubMed ID: 23351021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
    Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
    Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should we aim at tissue renin-angiotensin systems?
    Smits JF; Passier RC; Daemen MJ
    Pharm World Sci; 1998 Jun; 20(3):93-9. PubMed ID: 9618731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of converting enzyme inhibitors on renin-angiotensin system in normal rats.
    Komori T; Takada T; Funae Y; Yamamoto K
    Osaka City Med J; 1984 Jun; 30(1):17-30. PubMed ID: 6096787
    [No Abstract]   [Full Text] [Related]  

  • 11. Renin-Angiotensin System Modulation in Adults With COVID-19.
    Dos Santos RAS; Taccone FS; Annoni F
    JAMA; 2023 Aug; 330(7):663-664. PubMed ID: 37581678
    [No Abstract]   [Full Text] [Related]  

  • 12. Tissue renin-angiotensin systems and their modulation: the heart as a paradigm for new aspects of converting enzyme inhibition.
    Lindpaintner K; Ganten D
    Cardiology; 1991; 79 Suppl 1():32-44. PubMed ID: 1655263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of chronic captopril treatment on circulating and tissue renin-angiotensin system in SHR rats.
    Hu WY; Chen DG; Chen SC; Jin XQ; Wang HJ
    Zhongguo Yao Li Xue Bao; 1996 Nov; 17(6):507-12. PubMed ID: 9863143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developmental biology of angiotensin-converting enzyme.
    Yosipiv IV; El-Dahr SS
    Pediatr Nephrol; 1998 Jan; 12(1):72-9. PubMed ID: 9502575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of converting enzyme inhibitors.
    Unger T; Gohlke P
    Am J Cardiol; 1990 May; 65(19):3I-10I. PubMed ID: 2159693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diverse factors influencing angiotensin metabolism during ACE inhibition: insights from molecular biology and genetic studies.
    Morgan K
    Br Heart J; 1994 Sep; 72(3 Suppl):S3-10. PubMed ID: 7946800
    [No Abstract]   [Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction.
    Pfeffer JM; Fischer TA; Pfeffer MA
    Annu Rev Physiol; 1995; 57():805-26. PubMed ID: 7778884
    [No Abstract]   [Full Text] [Related]  

  • 18. Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition.
    Vaughan DE
    Clin Cardiol; 1997 Nov; 20(11 Suppl 2):II-34-7. PubMed ID: 9422850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Converting enzyme inhibitors in cardiovascular therapy: current status and future potential.
    Unger T; Gohlke P
    Cardiovasc Res; 1994 Feb; 28(2):146-58. PubMed ID: 8143294
    [No Abstract]   [Full Text] [Related]  

  • 20. ACE inhibitors: future perspectives.
    Reid JL
    J Cardiovasc Pharmacol; 1993; 22 Suppl 1():S41-3. PubMed ID: 7507539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.